Literature DB >> 9164992

Acarbose enhances human colonic butyrate production.

G A Weaver1, C T Tangel, J A Krause, M M Parfitt, P L Jenkins, J M Rader, B A Lewis, T L Miller, M J Wolin.   

Abstract

Earlier studies suggest that butyrate has colonic differentiating and nutritional effects and that acarbose increases butyrate production. To determine the effects of acarbose on colonic fermentation, subjects were given 50-200 mg acarbose or placebo (cornstarch), three times per day, with meals in a double-blind crossover study. Fecal concentrations of starch and starch-fermenting bacteria were measured and fecal fermentation products determined after incubation of fecal suspensions with and without added substrate for 6 and 24 h. Substrate additions were cornstarch, cornstarch plus acarbose and potato starch. Dietary starch consumption was similar during acarbose and placebo treatment periods, but fecal starch concentrations were found to be significantly greater with acarbose treatment. Ratios of starch-fermenting to total anaerobic bacteria were also significantly greater with acarbose treatment. Butyrate in feces, measured either as concentration or as percentage of total short-chain fatty acids, was significantly greater with acarbose treatment than with placebo treatment. Butyrate ranged from 22.3 to 27.5 mol/100 mol for the 50-200 mg, three times per day doses of acarbose compared with 18.3-19.3 mol/100 mol for the comparable placebo periods. The propionate in fecal total short-chain fatty acids was significantly less with acarbose treatment (10.7-12.1 mol/100 mol) than with placebo treatment (13.7-14.2 mol/100 mol). Butyrate production was significantly greater in fermentations in samples collected during acarbose treatment, whereas production of acetate and propionate was significantly less. Fermentation decreased when acarbose was added directly to cornstarch fermentations. Acarbose effectively augmented colonic butyrate production by several mechanisms; it reduced starch absorption, expanded concentrations of starch-fermenting and butyrate-producing bacteria and inhibited starch use by acetate- and propionate-producing bacteria.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164992     DOI: 10.1093/jn/127.5.717

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  27 in total

1.  Effect of dietary fat to starch content on fecal microbiota composition and activity in dogs1.

Authors:  Sofia Schauf; Gabriel de la Fuente; Charles J Newbold; Anna Salas-Mani; Celina Torre; Leticia Abecia; Carlos Castrillo
Journal:  J Anim Sci       Date:  2018-09-07       Impact factor: 3.159

2.  Changes of fermentation pathways of fecal microbial communities associated with a drug treatment that increases dietary starch in the human colon.

Authors:  M J Wolin; T L Miller; S Yerry; Y Zhang; S Bank; G A Weaver
Journal:  Appl Environ Microbiol       Date:  1999-07       Impact factor: 4.792

3.  In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis.

Authors:  E J Simpson; M A Chapman; J Dawson; D Berry; I A Macdonald; A Cole
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

4.  Formate-dependent growth and homoacetogenic fermentation by a bacterium from human feces: description of Bryantella formatexigens gen. nov., sp. nov.

Authors:  Meyer J Wolin; Terry L Miller; Matthew D Collins; Paul A Lawson
Journal:  Appl Environ Microbiol       Date:  2003-10       Impact factor: 4.792

5.  Sex-dependent Differences in Liver and Gut Metabolomic Profiles With Acarbose and Calorie Restriction in C57BL/6 Mice.

Authors:  Victoria K Gibbs; Rachel A Brewer; Nathan D Miyasaki; Amit Patki; Daniel L Smith
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-01-16       Impact factor: 6.053

6.  The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer.

Authors:  Shien Hu; Tien Sy Dong; Sushila R Dalal; Feng Wu; Marc Bissonnette; John H Kwon; Eugene B Chang
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

7.  Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.

Authors:  Daniel L Smith; Rachael M Orlandella; David B Allison; Lyse A Norian
Journal:  Geroscience       Date:  2020-10-02       Impact factor: 7.713

8.  Habitual Dietary Intake Affects the Altered Pattern of Gut Microbiome by Acarbose in Patients with Type 2 Diabetes.

Authors:  Fumie Takewaki; Hanako Nakajima; Daiki Takewaki; Yoshitaka Hashimoto; Saori Majima; Hiroshi Okada; Takafumi Senmaru; Emi Ushigome; Masahide Hamaguchi; Masahiro Yamazaki; Yoshiki Tanaka; Shunji Nakajima; Hiroshi Ohno; Michiaki Fukui
Journal:  Nutrients       Date:  2021-06-19       Impact factor: 5.717

9.  Decrease in oxidative phosphorylation yield in presence of butyrate in perfused liver isolated from fed rats.

Authors:  Jean-Louis Gallis; Pierre Tissier; Henri Gin; Marie-Christine Beauvieux
Journal:  BMC Physiol       Date:  2007-08-28

10.  Butyrate ingestion improves hepatic glycogen storage in the re-fed rat.

Authors:  Marie-Christine Beauvieux; Hélène Roumes; Nadège Robert; Henri Gin; Vincent Rigalleau; Jean-Louis Gallis
Journal:  BMC Physiol       Date:  2008-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.